Taken together, these findings suggest that T-cell lymphoma cells expressing high levels of RARA are particularly chemosensitive to RARA-directed retinoids, and that measuring RARA protein expression—but not necessarily identifying RARA mutations—might be used predict this degree of chemosensitivity. The gene discussed is RARA; the disease is T-cell non-Hodgkin lymphoma.